These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

257 related items for PubMed ID: 9718376

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Conversion from subcutaneous to intravenous erythropoietin in a hemodialysis population.
    Vercaigne LM, Collins DM, Penner SB.
    J Clin Pharmacol; 2005 Aug; 45(8):895-900. PubMed ID: 16027399
    [Abstract] [Full Text] [Related]

  • 3. A comparison between once-weekly and twice- or thrice-weekly subcutaneous injection of epoetin alfa: results from a randomized controlled multicentre study.
    Lee YK, Kim SG, Seo JW, Oh JE, Yoon JW, Koo JR, Kim HJ, Noh JW.
    Nephrol Dial Transplant; 2008 Oct; 23(10):3240-6. PubMed ID: 18469158
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
    Besarab A, Salifu MO, Lunde NM, Bansal V, Fishbane S, Dougherty FC, Beyer U, Ba16285 Study Investigators.
    Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
    [Abstract] [Full Text] [Related]

  • 5. Subcutaneous compared with intravenous epoetin treatment in patients on hemodialysis: one center study.
    Malovrh M, Premru V.
    Ther Apher Dial; 2005 Jun; 9(3):233-6. PubMed ID: 15966996
    [Abstract] [Full Text] [Related]

  • 6. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin.
    Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA.
    N Engl J Med; 1998 Aug 27; 339(9):584-90. PubMed ID: 9718377
    [Abstract] [Full Text] [Related]

  • 7. Haemoglobin response to subcutaneous versus intravenous epoetin alfa administration in iron-replete haemodialysis patients.
    Leikis MJ, Kent AB, Becker GJ, McMahon LP.
    Nephrology (Carlton); 2004 Jun 27; 9(3):153-60. PubMed ID: 15189176
    [Abstract] [Full Text] [Related]

  • 8. Effect of switching from subcutaneous to intravenous administration of epoetin-alpha in haemodialysis patients: results from a Swedish multicentre survey.
    Linde T, Furuland H, Wikström B.
    Scand J Urol Nephrol; 2005 Jun 27; 39(4):329-33. PubMed ID: 16118109
    [Abstract] [Full Text] [Related]

  • 9. Long-term safety and tolerability of epoetin zeta, administered intravenously, for maintenance treatment of renal anemia.
    Baldamus C, Krivoshiev S, Wolf-Pflugmann M, Siebert-Weigel M, Koytchev R, Bronn A.
    Adv Ther; 2008 Nov 27; 25(11):1215-28. PubMed ID: 18931828
    [Abstract] [Full Text] [Related]

  • 10. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease.
    Ifudu O, Feldman J, Friedman EA.
    N Engl J Med; 1996 Feb 15; 334(7):420-5. PubMed ID: 8552143
    [Abstract] [Full Text] [Related]

  • 11. National cooperative rHu erythropoietin study in patients with chronic renal failure: a phase IV multicenter study. Report of National Cooperative rHu Erythropoietin Study Group.
    Nissenson AR.
    Am J Kidney Dis; 1991 Oct 15; 18(4 Suppl 1):24-33. PubMed ID: 1928075
    [Abstract] [Full Text] [Related]

  • 12. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V, Rutkowski B, Baldamus C, Scigalla P, Koytchev R, Epoetin Zeta Study Group.
    Curr Med Res Opin; 2008 Mar 15; 24(3):625-37. PubMed ID: 18208642
    [Abstract] [Full Text] [Related]

  • 13. Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia.
    Krivoshiev S, Wizemann V, Czekalski S, Schiller A, Pljesa S, Wolf-Pflugmann M, Siebert-Weigel M, Koytchev R, Bronn A, Epoetin Zeta Study Group.
    Adv Ther; 2010 Feb 15; 27(2):105-17. PubMed ID: 20369312
    [Abstract] [Full Text] [Related]

  • 14. Subcutaneous erythropoietin results in lower dose and equivalent hematocrit levels among adult hemodialysis patients: Results from the 1998 End-Stage Renal Disease Core Indicators Project.
    McClellan WM, Frankenfield DL, Wish JB, Rocco MV, Johnson CA, Owen WF, End-Stage Renal Disease Core Indicators Work Group.
    Am J Kidney Dis; 2001 May 15; 37(5):E36. PubMed ID: 11325701
    [Abstract] [Full Text] [Related]

  • 15. Is it time to reconsider subcutaneous administration of epoetin?
    Patel TV, Robinson K, Singh AK.
    Nephrol News Issues; 2007 Oct 15; 21(11):57, 59, 63-4 passim. PubMed ID: 17970510
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
    Smith WB, Dowell JA, Pratt RD.
    Clin Ther; 2007 Jul 15; 29(7):1368-80. PubMed ID: 17825688
    [Abstract] [Full Text] [Related]

  • 17. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
    Voravud N, Sriuranpong V, Suwanrusme H.
    J Med Assoc Thai; 2007 Jun 15; 90(6):1082-8. PubMed ID: 17624200
    [Abstract] [Full Text] [Related]

  • 18. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC).
    Pizzarelli F, David S, Sala P, Icardi A, Casani A.
    Am J Kidney Dis; 2006 Jun 15; 47(6):1027-35. PubMed ID: 16731298
    [Abstract] [Full Text] [Related]

  • 19. The effect of a change in epoetin alfa reimbursement policy on anemia outcomes in hemodialysis patients.
    Berns JS, Fishbane S, Elzein H, Lynn RI, Deoreo PB, Tharpe DL, Meisels IS.
    Hemodial Int; 2005 Jul 15; 9(3):255-63. PubMed ID: 16191075
    [Abstract] [Full Text] [Related]

  • 20. Comparison of the therapeutic efficacy of epoetin beta and epoetin alfa in maintenance phase hemodialysis patients.
    Loughnan A, Ali GR, Abeygunasekara SC.
    Ren Fail; 2011 Jul 15; 33(3):373-5. PubMed ID: 21401367
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.